Company intelligence / Profile preview

Addimmune

Rockville, Maryland, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Phase 1 trial of AGT103-T (single-infusion gene therapy) showed positive safety in all seven patients: 100% engraftment, expansion, and reactivity of modified T cells to HIV; no serious adverse events or cell rejection at 180 days. Follow-on studies showed immune responses and viral suppression in several participants, aiming for a one-time functional cure freeing patients from lifelong antiretroviral therapy. Finalized results pending peer review publication.

Therapeutic areas: Infectious Diseases
Modalities: Gene therapyCell therapy
Industry: Biotech

Partnerships

SPAC merger with 10X Capital Venture Acquisition Corp. IIIEquity facility agreement with Cantor Fitzgerald

Beyond the preview

Go deeper on Addimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Addimmune.

Explore the full profile